Haynes & Boone Guides Oncocyte Through Securities Offering
February 11, 2025
February 11, 2025
DALLAS, Texas, Feb. 11 -- Haynes and Boone, a law firm, issued the following news release:
Haynes Boone advised Oncocyte Corp. (Nasdaq: OCX) on a successful $29.1 million registered direct offering and concurrent private placement.
The financing, led by Oncocyte's five largest shareholders, is expected to fully fund the company's FDA In-Vitro Diagnostic (IVD) transplant assay program through regulatory approval and commercialization.
The transacti . . .
Haynes Boone advised Oncocyte Corp. (Nasdaq: OCX) on a successful $29.1 million registered direct offering and concurrent private placement.
The financing, led by Oncocyte's five largest shareholders, is expected to fully fund the company's FDA In-Vitro Diagnostic (IVD) transplant assay program through regulatory approval and commercialization.
The transacti . . .